Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256399 · ClinicalTrials.gov registry record · NA
Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)
A NA study of Erectile Dysfunction and BPH, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00256399: Completed NA study of Erectile Dysfunction and BPH, sponsored by University Hospitals Cleveland Medical Center.
NCT00256399 is a NA study of Erectile Dysfunction and BPH that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 6 participants, below the 231-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00256399, a NA study of Erectile Dysfunction and BPH, has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.
Conditions Studied
Interventions
- DRUG Alfuzosin 10 mg
Study Locations (1)
Ohio
- University Hospitals of Cleveland - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-05-08 |
| Phase | NA |
What the finished NCT00256399 record still lists
NCT00256399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 231-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Erectile Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Alfuzosin 10 mg is the first listed.
NCT00256399 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00256399 about?
NCT00256399 is a clinical study titled "Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)". Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.
What is the current status of trial NCT00256399?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2005-11. Estimated completion is 2007-05-08.
What conditions does trial NCT00256399 study?
This clinical trial studies the following conditions: Erectile Dysfunction, BPH.
What interventions are being tested in trial NCT00256399?
The interventions under investigation include: Alfuzosin 10 mg (DRUG).
Who is sponsoring clinical trial NCT00256399?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00256399 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erectile Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00256399's enrollment target sits among peer trials
6 32nd of 33 higher than 1 of 33 other Erectile Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Erectile Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
RECRUITING · NA
-
Double-S: a Wearable Device for Erectile Dysfunction
RECRUITING · NA
-
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
RECRUITING · NA
-
The Impact of Dietary Pattern on Erectile Function
RECRUITING · NA
-
Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain
RECRUITING · NA
-
The Impact of a Plant-based Meat Meal Versus an Animal Meat Meal on Erectile Function in Healthy Men.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia